Hematology / Oncology CE Activities

A Balancing Act: Safety and Success in CMV Management for HCT Patients: A Clinical Forum®

1.0 CE Credit(s)

A Violent Graft in a Vulnerable Host: The Future of aGvHD Management: A Care Team Forum®

1.5 CE Credit(s)

Rapid Recognition and Management of T-Cell Therapy-Related Toxicities in B-Cell Lymphomas: Crucial Updates for the Emergency Department

1.0 CE Credit(s)

Immunotherapy for NMSC: Key Insights for Oncology, Dermatology, and Infusion Nurses: A Clinical Transfers®

1.0 CE Credit(s)

Preventing and Treating Acute GvHD: A Discussion of Real-World Cases

1.0 CE Credit(s)

An Interprofessional Approach to Managing Treatment-Related Complications of Acute GvHD

0.25 CE Credit(s)

Steroid Dependent Acute GvHD: An Interprofessional Approach

0.25 CE Credit(s)

Immunotherapy for NMSC: Key Insights for Oncology, Dermatology, and Infusion Nurses

1.0 CE Credit(s)

Advances in Precision Medicine for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Care: A Care Team Forum®

1.25 CE Credit(s)

Collaboration Nation: Interprofessional Perspectives on Immunotherapy and Team-Based Care for Non-Melanoma Skin Cancer

0.5 CE Credit(s)

Closing the Gap: Personalized Approaches to Cervical Cancer Screening and Treatment

0.5 CE Credit(s)

Hematology / oncology blog

Targeting BCMA: A New Path in Relapsed/Refractory Multiple Myeloma

In triple- and quad-refractory myeloma, median survival was only about 9 months, and less than 6 months in penta-refractory disease.

Hematology / Oncology
Blog

Navigating Immunotherapy in Advanced NSCLC: What Every Oncologist Should Know

The advent of immunotherapy has significantly extended survival and revolutionized care in advanced non-small cell lung cancer (NSCLC).

Hematology / Oncology
Blog

Is Immunotherapy Right for Your Patient with Nonmelanoma Skin Cancer?

The primary goal of treatment in nonmelanoma skin cancer (NMSC) is tumor elimination with maximal preservation of function and cosmesis.

Hematology / Oncology
Blog

RMEI Presentations

Answering the Call to Action: How Nurses Have Become Progressively More Involved in Immunotherapy IME (2018 to Present)

Optimizing treatment in BCC and CSCC: 3 years of oncology CME

Iterative Data-Driven Education for Evolving Strategies of Care in cSCC

When the Patient Voice is Heard in Education, Does the Clinician Listen?

RMEI DECISION SUPPORT AIDS

Intravitreal Anti-VEGF & Bispecific Therapies for DME & nAMD

In late 2022, the ocular implant, insertion tool assembly, (including the drug vial & initial fill needle) for ranibizumab PDS were voluntarily recalled due to septum dislodgement and paused implantations including ongoing global clinical trials; this did not include the refill vial and needle.

Hematology / Oncology
Decision Support Aid

Cervical Cancer: What You Need to Know About Screening, Symptoms, and Treatments

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients. An estimated 13,960 women are diagnosed with invasive cervical cancer every year.

Hematology / Oncology
Decision Support Aid

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

Hematology / Oncology
Decision Support Aid

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.

Hematology / Oncology
Decision Support Aid

LATEST HEMATOLOGY / ONCOLOGY ARTICLES

Latest Hematology / Oncology Articles

Extrachromosomal DNA — Amping Up Cancer April 10, 2025
A recent study shows how extrachromosomal DNA contributes to tumor heterogeneity and may drive cancer progression.
Lillian L. Siu, Trevor J. Pugh
Targetable Mutations in BRAF V600E–Negative Hairy-Cell Leukemia April 10, 2025
Patients with hairy-cell leukemia lacking the BRAF V600E mutation often have a BRAF deletion or activating mutation in MAP2K1, with a poor response to standard therapy. Dabrafenib plus trametinib was active in one patient.
Alessia Santi, Alessandra Venanzi, Alessandra Pucciarini, Gianluca Schiavoni, Marta Naccari, Elisa Albi, Lorenzo De Paoli, Tamara Intermesoli, Stefano Lazzi, Esmeralda Conte, Alessandro Mancini, Brunangelo Falini, Alessandro Gozzetti, Gianna M. D’Elia, Angelo Genua, Enrico Tiacci
A Polygenic Risk Score in Practice April 10, 2025
After decades of undergoing epidemiologic study, prostate cancer remains an enigmatic disease; the only established risk factors are older age, family history of prostate cancer, and African ancestry1 (apart from uncommon cases among men with variants in the genes associated with hereditary breast cancer and the Lynch syndrome)....
David J. Hunter

RMEI LIGHTNING TALKS

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.

Allergy & Immunology
2021

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.

Gastroenterology
2021

Hematology / Oncology CE Activities

Hematology / oncology blog

Targeting BCMA: A New Path in Relapsed/Refractory Multiple Myeloma

Navigating Immunotherapy in Advanced NSCLC: What Every Oncologist Should Know

Is Immunotherapy Right for Your Patient with Nonmelanoma Skin Cancer?

RMEI Presentations

Answering the Call to Action: How Nurses Have Become Progressively More Involved in Immunotherapy IME (2018 to Present)

Optimizing treatment in BCC and CSCC: 3 years of oncology CME

Iterative Data-Driven Education for Evolving Strategies of Care in cSCC

When the Patient Voice is Heard in Education, Does the Clinician Listen?

RMEI DECISION SUPPORT AIDS

Intravitreal Anti-VEGF & Bispecific Therapies for DME & nAMD

Cervical Cancer: What You Need to Know About Screening, Symptoms, and Treatments

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

LATEST HEMATOLOGY / ONCOLOGY ARTICLES

RMEI LIGHTNING TALKS

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

Previously Published CE Activities